|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In addition, PSG-1 decreased the tumor weight and increased the apoptosis rate and caspase-3 and caspase-9 activities of tumor derived from the C3H/HeN mice.
|
25549720 |
2015 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In contrast, administration of PSG-1 markedly suppressed tumor growth in CT26 tumor-bearing mice.
|
24506418 |
2014 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Cultured NSCLC cells expressed higher levels of SP-1 protein than normal airway epithelial cells, and double-fluorescence immunohistochemistry showed a strong correlation between SP-1 and VEGF in human NSCLC tumors.
|
22992725 |
2012 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Combined, this data strongly suggests that PSG1 could be a promising treatment option for patients with aGVHD following bone marrow transplantation for a nonmalignant condition, such as an autoimmune disorder or a genetic immunodeficiency.
|
30253241 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
On the other hand, administration of PSG1 was less effective in managing aGVHD in the presence of an alloimmune reaction against a malignancy in a graft-versus-leukemia experimental model.
|
30253241 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these data provide evidence that PSG-1 can be employed as an alternative dietary supplement to ameliorate T1DM.
|
31616874 |
2019 |
|
Precancerous Conditions
|
0.010 |
Biomarker
|
group |
BEFREE |
Combined, this data strongly suggests that PSG1 could be a promising treatment option for patients with aGVHD following bone marrow transplantation for a nonmalignant condition, such as an autoimmune disorder or a genetic immunodeficiency.
|
30253241 |
2019 |
|
Acute GVH disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
As the role of CD4<sup>+</sup>FoxP3<sup>+</sup> cells in the prevention of aGVHD is well established, we tested whether PSG1 has beneficial effects in a murine aGHVD transplantation model.
|
30253241 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Although PSG1 did not affect EVT invasion in the in vitro assays employed, we found that the serum PSG1 concentration is lower in African-American women diagnosed with early-onset and late-onset preeclampsia, a pregnancy pathology characterized by shallow trophoblast invasion, than in their respective healthy controls only when the fetus was a male; therefore, the reduced expression of this molecule should be considered in the context of preeclampsia as a potential therapy.
|
31683744 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
On the other hand, administration of PSG1 was less effective in managing aGVHD in the presence of an alloimmune reaction against a malignancy in a graft-versus-leukemia experimental model.
|
30253241 |
2019 |
|
SVEINSSON CHORIORETINAL ATROPHY
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that PSG-1 pretreatment effectively reduced the levels of malondialdehyde (MDA), but increased the activity of catalase (CAT), superoxide dismutase (SOD), glutathione (GSH) and the total glutathione (T-GSH), and significantly reduced oxidative stress in AA treated rats.
|
31464322 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to the 8<sup>th</sup>-edition of the tumor-nodes-metastasis-classification localized prostate cancer (PCa) can be divided into two categories (cT1,cT2), two stages (SI,SII), and, by incorporating prostate-specific-antigen (PSA) and WHO-grade (Gleason-Score), into prognostic stage groups (PSG I,IIA,IIB,IIC,III).
|
30176542 |
2018 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to the 8<sup>th</sup>-edition of the tumor-nodes-metastasis-classification localized prostate cancer (PCa) can be divided into two categories (cT1,cT2), two stages (SI,SII), and, by incorporating prostate-specific-antigen (PSA) and WHO-grade (Gleason-Score), into prognostic stage groups (PSG I,IIA,IIB,IIC,III).
|
30176542 |
2018 |
|
Mitochondrial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, administration of PSG-1 suppressed DOX-induced mitochondrial disorders, which was evidenced by reducing reactive oxygen species, elevating mitochondrial membrane potential and inhibiting the opening of mitochondrial permeability transition pore.
|
30287039 |
2018 |
|
Endothelial dysfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Taken together, these findings suggested that PSG-1 could be as a promising adjuvant against endothelial dysfunction through ameliorating oxidative stress and apoptosis.
|
28108410 |
2017 |
|
Immunosuppression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings have demonstrated that PSG-1 may ameliorate CTX-induced immunosuppression through reducing apoptosis and oxidative damage in immunological system.
|
27913287 |
2017 |
|
Papillary thyroid carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PLAU, PSG1 and EGR2 were the crucial TFs with higher transcriptional activity in PTC than in control.
|
26708423 |
2016 |
|
estrogen receptor-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibiting PSG1 can effectively reduce chemoresistance via a transforming growth factor-β (TGF-β)-related pathway in ER-negative breast cancer cells.
|
27653744 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Cultured NSCLC cells expressed higher levels of SP-1 protein than normal airway epithelial cells, and double-fluorescence immunohistochemistry showed a strong correlation between SP-1 and VEGF in human NSCLC tumors.
|
22992725 |
2012 |
|
Parkinsonian Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
This kindred (PSG-1) is included in the 'frontotemporal dementias and Parkinsonism linked to chromosome 17' group along with kindreds affected by apparently different forms of atypical dementias.
|
10202939 |
1999 |
|
Frontotemporal dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This kindred (PSG-1) is included in the 'frontotemporal dementias and Parkinsonism linked to chromosome 17' group along with kindreds affected by apparently different forms of atypical dementias.
|
10202939 |
1999 |